Navigation Links
Hadasit to Present at the Rodman & Renshaw Annual Global Investment Conference on September 13, 2011
Date:8/31/2011

NEW YORK, Aug. 31, 2011 /PRNewswire/ -- Hadasit Bio-Holdings, Ltd. - (OTCBB: HADSY), a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, announced today that its CEO, Mr. Ophir Shahaf, will present at the Rodman & Renshaw Annual Global Investment Conference in New York City on Tuesday, September 13, 2011 at 12:05 p.m. ET.  The conference will be held at the Waldorf Astoria Hotel.

Investors attending the conference who wish to meet with Mr. Shahaf for a one-on-one meeting should contact their Rodman & Renshaw representative directly.

About Hadasit Bio-Holdings:
Hadasit Bio-Holdings Ltd., established in 2006, is the publicly traded subsidiary of Hadasit Ltd. - the technology transfer company of the Hadassah University Hospital, Israel's foremost medical research center.  The Company was established for the purpose of promoting and commercializing the intellectual property and R&D capabilities generated by Hadassah.

HADSY is the domestically traded ADR of Hadasit Bio-Holdings, a public investment vehicle representing a portfolio of biotech companies, all based on inventions developed at Hadassah.  

Hadasit Bio-Holdings focuses on advancing companies that are past successful preclinical trials and close to completion of Phase I/II clinical trials. The portfolio companies develop drugs with blockbuster potential (markets that are worth over a billion dollars) and operate in the fields of cancer, inflammatory diseases and tissue regeneration using stem cells - areas in which the Hadassah Hospital has extensive knowledge and recognition as a global leader.

For more information please visit: www.hbl.co.il.

Investor Contact
KCSA Strategic Communications
Jeff Corbin / Rob Fink

SOURCE Hadasit Bio-Holdings, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Clinical Developments at Enlivex Therapeutics - a Hadasit Bio-Holdings Portfolio Company
2. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
3. PAREXEL International to Present at Robert Baird Healthcare Conference and William Blair Emerging Growth Stock Conference
4. Life Technologies to Present at the UBS 2011 Global Life Sciences Conference
5. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
6. Bacterin International to Present at Stifel Nicolaus 2011 Healthcare Conference on September 8, 2011
7. Amgen Highlights Data to Be Presented at American Society for Bone and Mineral Research Meeting
8. Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
9. Interleukin Genetics, Inc. to Present at the 2011 Wedbush Securities Life Sciences Management Access Conference
10. Dendreon Announces Webcast Presentation at Canaccord Genuity Growth Conference
11. Omeros to Present at Two Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... ... August 28, 2015 , ... ... presented two studies at the International Spine Intervention Society’ s 23rd ... through to August 1st, 2015. With a focus on evidence-based research and clinical ...
(Date:8/27/2015)... ... August 27, 2015 , ... The Kansas City Animal Health ... animal health companies to hear from animal health companies with the newest technology. ... licensing agreements or distribution contracts. This meeting is one of the only ...
(Date:8/27/2015)... MENLO PARK, Calif. , Aug. 27, 2015 /PRNewswire/ ... company in the emerging field of regenerative medicine, today ... two investor conferences in the month of September.  ... Officer, will present at Rodman & Renshaw,s 17th Annual ... 10:25am ET/7:25am PT at the St. Regis Hotel in ...
(Date:8/27/2015)... ... August 27, 2015 , ... METTLER TOLEDO's web-based ... the product choices to a manageable shortlist of bench and floor scales and ... that fit best with the customer’s industry and application. , Side-by-side product ...
Breaking Biology Technology:Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 2Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 3Proove Biosciences Presents New Research Study at the International Spine Intervention Society’s Annual Scientific Meeting 4VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 2VetStem Biopharma, Inc. Among Seventeen Companies Selected to Present at the KC Animal Health Investment Forum on September 1st 2015 3Asterias Biotherapeutics to Present at Upcoming Investor Conferences 2METTLER TOLEDO Updates Online Scale Selection Tool 2
... Inc., developer of the VerifyNow® System, the first rapid and easy-to-use point-of-care system ... results of the GRAVITAS trial have been published in T he ... m erican M e dic a ... i o n (1). First presented at the American ...
... 15, 2011 The following is being issued by the ... Obama,s push for a greater investment in U.S. science, technology, ... of CNBC,s Sunday, March 13, broadcast of " The Wall ... interviews with The Pew Charitable Trusts President and ...
... CAMBRIDGE, Mass., March 15, 2011 Biotechnology company ... operations in Cambridge, Massachusetts and is advancing its ... and monitoring tool for celiac disease. The company ... targeted immunotherapies from Nexpep Pty., Ltd., based in ...
Cached Biology Technology:Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA 2Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA 3Investing in Biomedical Innovation 2Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 2Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 3Start-Up ImmusanT Seeks to Restore Tolerance to Gluten in Celiac Disease with Immunotherapy 4
(Date:8/5/2015)... New York , August 5, 2015 ... market report titled "Facial Recognition Market - Global Industry ... 2022", the global market for facial recognition is forecast ... is driven by increased demand for surveillance systems by ... the rising number of crimes and terrorist activities across ...
(Date:8/4/2015)... 4, 2015  AMRI (NASDAQ: AMRI ) today reported financial ... Highlights: , Second quarter contract revenue of ... , Adjusted contract margins of 26 ... including a $0.05 decrease in EPS from royalties in the current ... "We are very pleased to present another strong ...
(Date:7/31/2015)... de julio de 2015 BGI llevará a cabo ... del 22 al 25 de octubre de 2015, en ... conferencia celebra su décimo aniversario este año. Desde su ... de las reuniones anuales más influyentes del mundo en ... las conferencias científicas más dinámicas, entusiastas y amenas. ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3
... found that many doctors report that they do not ... services to their female patients. Published early online in ... Cancer Society, the study indicates that efforts are needed ... them for average-risk women. Women with mutations in ...
... Tel Aviv Since 1999, several outbreaks of West ... is transmitted from birds to humans by blood-sucking mosquitoes, have ... But researchers aren,t certain how the virus migrated here ... next. Now Prof. Ella Mendelson of Tel Aviv University,s ...
... the August issue of Nature Medicine has ... patients with Hodgkin,s lymphoma are most likely to develop ... who is at risk could help physicians tailor treatment ... susceptible to long-term damage. Hodgkin,s lymphoma is one ...
Cached Biology News:Mismatch between cancer genetics counseling and testing guidelines and physician practices 2Catching the West Nile virus in action 22 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 22 genetic variations predict second cancers after radiation for children with Hodgkin lymphoma 3
prototype Nco I...
... collected via cardiac puncture from 3 to 4 ... It is then centrifuged and frozen at -70C. ... bottled at 4C then stored at -70C. DIRECT ... USED PEL-FREEZ COMPLEMENT, YOU CAN NOW BUY DIRECTLY ...
These disposable button tethers are designed for rat infusion studies lasting more than 2 weeks. After one to two weeks the subcutaneous tissue will grow into the Dacron mesh, making the sutures irre...
Performance, mycoplasma, virus, and endotoxin tested...
Biology Products: